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Abstract
Hypothalamic-pituitary function was evaluated in a combination of tests
with four hypothalamic releasing hormones (4RHs) and L-dopa in normal
subjects and in patients with hypothalamic and/or pituitary disorders. Plasma
concentrations of anterior pituitary hormones (GH, ACTH, TSH, PRL, LH
and FSH) were measured before and after simultaneous iv administration of
GHRH, CRH, TRH and LHRH. In addition, changes in the plasma levels
of GHRH and GH were investigated before and after oral administration of
L-dopa. Normal subjects showed appreciable responses to both tests. In five
patients with hypothalamic disorders, the response of plasma anterior pituitary
hormones varied, but plasma GHRH and GH did not respond to L-dopa.
Patients with idiopathic and postpartum hypopituitarism showed low response
to 4RHs or none at all, but L-dopa evoked a normal GHRH response in 2
of the 4 cases having no GH response. In the patients with hypopituitarism
due to resection of a pituitary tumor, the response of anterior pituitary hor-
mones to 4RHs was low, and L-dopa administration induced a normal
GHRH and low GH response in 5 out of the 7 cases. AFter 4RHs
administration, the patients with ACTH deficiency syndrome showed different
patterns of impaired ACTH secretion, and isolated, combined or limited
ACTH reserve. Seven patients with anorexia nervosa showed exaggerated GH,
delayed TSH and FSH, low ACTH and LH, that is, normal PRL response to
4RHs, but no response of plasma GHRH or GH to L-dopa, suggesting the
presence of hypothalamic dysfunction. These results indicate that the com-
bination of the 4RHs test and L-dopa test is a simple and useful means for
evaluating hypothalamic-pituitary function by measuring the response of plasma
GHRH and six anterior pituitary hormones in the patients with endocrine
disorders.
Following the discovcry of TRH(1969),
LHRH (1970)and CRH (1981), GHRH
was is lated in 1982 by Guillemin et al.
and Rivier er c/. Since then, there has
been considerable advance in studies on
the hypothalamic control of anterior pitui-Received May 12, 1989
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tary hormone secretion. One of the clinical
applications of these hypothalamic releasing
hormones (RHs) was simultaneous intra-
venous administration of 4RHs (GHRH,
CRH, TRH, LHRH) to evaluate pituitary
function (Sheldon et al., 1985; Cohen 'er
al., 1986). On the other hand, we have
investigated the mechanism of GHRH
release and its physiopathological role in
normal and diseased states using a sensitive
and specific radioimmunoassay (RIA) for
GHRH (Saito et al., 1984; Sano et al.,
1986; Yamasaki el al., 1988a). First we
found that oral administration of L-dopa
induces GH secretion by stimulating hypo-
thalamic GHRH release (Saito el ol., 1984).
This was confirmed by Donnadieu et al.
(1985) and Chihara et al. (1986). In this
study, we describe the usefulness of the
combination of tests with 4RHs and L-
dopa to evaluate hypothalamic-pituitary




Six normal male adults aged 20 25 years
without obesity or endocrine disorders were
examined as controls. The patients studied
consisted ol 5 hypothalamic disorders, I I hy-
popituitalism of various causes, 3 ACTH
deficiency syndrome and 7 anorexia nervosa(Table l). The diagnosis was confirmed by
clinical manifestations and data on hormonal
and morphological examinations. The study
was approved by the Human Subjects Protection
Commitee, School of Medicine, the University
of Tokushima, and the informed consent for the
study was obtained from all volunteers and
patients.
The tests were performed during bed rest
after an overnight fast. At least 30 min prior
to the start of each test, a 2l-gauge indwelling
needle was inserted into the antecubital vein
and blood samples were taken through the
cannula serially before and after the administ-
ration ol 4RHs or L-dopa.
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Combined administration of four hupo-
thalamic releasing hormones
Synthetic preparation of GHRH (l-44) NH,
(100pg, Sumitomo Pharmaceutical Co., Osaka,
Japan), CRH (100 pg, Peptide Institute Inc.,
Japan), TRH (500 pg, Takeda Pharmaceutical
Co., Ltd, Tokyo, Japan) and LHRH (l00pg,
Tanabe Pharmaceutical Co., Ltd, Tokyo, Japan)
were simultaneously administered intravenously.
CRH was dissolved in sterile distilled water,
and filtered on a Millipore filter before use.
Blood samples were obtained serially at 0, 15,
30, 45, 60, 90 and 120 min after the administ
ration, and plasma concentrations of anterior
pituitary hormones (GH, ACTH, TSH, PRL, LH,
FSH) were measured.
Administration of L-dopa
A dose of 500 mg L-dopa was administered
orally to the subjects, and blood samples were
obtained serially at 0, 30, 45, 60,75, 90 and
120 min to measure the plasma concentrations
of GHRH and GH.
Radioimmunoassau for plasma GH, ACTH,
TSH, PRL, LH and FSH
The following RIA kits were used to measure
the plasma hormone concentration : GH, HGH-
II Dainabot, Tokyo, Japan; ACTH, ACTH
RIA-II, Compagnie Oris Industry S. A., France ;
TSH, MH-TSH, Corning, Ciba-Corning-Diag-
nostics, U. S. A. ; PRL, Prolactin RIA Kit, Sorin
Biomedica, France; LH and FSH LH and FSH
RIA Kit, Daiichi Radioisotope, Tokyo, Iapan.
Radioimmunoassdu for plasma GHRH
The extraction of GHRH from the plasma
was done as described previously (Saito et al.,
1984; Yamasaki et al., 1988b). In brief, samples
of 3.5 ml of plasma were mixed with 7 ml of
cold acetic acid-acetone solution (3: 100, vol/
vol) and the supernatant was mixed twice with
20 ml of petroleum ether. After the ether layer
was carefully removed and the remaining acetone
was eliminated by evaporation, the aqueous
portion was lyophilized. The residue was dis-
solved in assay buffer and subjected to RIA for
GHRH.
Synthetic GHRH (l 44) NH, (Takeda Chemi-
cal Industries, Ltd, Osaka, Japan) was labelled
with 12sl by the chloramine T method and the
iodinated product was purifled on a I X l0 cm
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man, Maidstone, England). The anti-GHRH
serum (RAS-8061, Peninsula Lab, San Carlos,
CA; lot No. 004118) used in this study failed
to crossreact with various neuropeptides and
recognized the N-terminal and part of the middle
portion of the amino acid sequence of hGHRH
(1-44) NHr. When synthetic GHRH (1 44) NH,
was used as the standard, the sensitivity of this
assay was 4 pg/tube. Since the extract from
I ml of plasma was dissolved in 100 pl of assay
buffer and used for the assay as well as 100 pl
of standard, the least detectable value was 4
pg/ml. Antibody bound and free tracers were
separated by double antibody method. The
rerovery of 30 pg of synthetic GHRH (1-44) NH,
added to l ml of plasma was 59.5+2.19/0. The
intra- and inter-assay coefficient of variation
were less than 100/6.
Statistical analysis
Data are expressed as means+SE. Unde-
tectable plasma hormone concentrations were
assigned as a value of the detection limit of the
assay to calculate mean values and increases.
The shaded areas indicating the normal range
in figures are expressed as the maximum and
minimum responses to the tests in normal sub-jects. The significance of differences in values




The responses of anterior pituitary
hormones to simultaneous intravenous
administration of 4RHs in six normal
subjects are shown in Fig. l. Plasma
levels of GH, ACTH, TSH, PRL, LH and
FSH increased and peaked at: GH, 25.4+
5.5 ng/ml at 45 min; ACTH, 62.0+10.7
pg/ml at 30min;TSH, 15.4+l.8ng/ml at
30 min ; PRL, 60.8 + I 1.4 ng/ml at 15 min ;
LH, 67.8+ 13.7 mlU/ml at 30 min ; and
FSH, 20.6 + 3.7 mlU/ml at 30 min. Changes
in plasma GHRH and GH after oral
administration of L-dopa in six normal
subjects are shown in Fig. 2. Basal and
peak plasma GHRH were ll.2+2.4 P8/m1,
and 31 .4 + 5.2 pgl ml, respectively. The
plasma GHRH concentration peaked usually
between 30-90 min after L-dopa adminis-
tration, which was 2-4 times the basal
level. Basal and peak plasma GH were
less than I ng/ml and 23.0+ 6.1 ng/ml,
respectively. The peak plasma GH concen-
tration was synchronized or l5-30 min be-
hind the peak plasma GHRH concentration.
Patients with hupothalamic disorders
The results of the 4RHs test in 5
patients with hypothalamic disorders (Cases
l-5) including I suprasellar germinoma, I
Hand-Schtiller-Christian disease, 2 cranio-
pharyngioma and I Prader-Willi syndrome
are shown in trig. 3. The plasma GH
response was normal or low, and the plasma
ACTH response was almost normal. Plasma
TSH showed a various responses: exagger-
ated (cases I and 5), delayed (cases
3 and 4) and normal (Case 2). Basal
plasma PRL was increased in 3 out of 5
patients, who also showed a exaggerated
response to 4RHs. Plasma LH and FSH
did not respond in cases l, 2 and 3, and
were subnormal in the other 2 cases.
In contrast, the L-dopa test revealed no
plasma GHRH or GH response in any of
these patients (Fig. a). In addition, insulin
hypoglycemia and arginine load failed to
evoke GH release in cases 1,2 and 5 who
received these tests (data not shown).
Patients with hupopituitarism
The results of the 4RHs test in 4
patients with idiopathic or postpartum
hypopituitarism (case 6-9) are shown in
Fig. 5. Plasma GH showed no response
in any, and plasma ACTH showed a low
response or none at all. Plasma TSH and
PRL showed a low response or none at all.
Plasma LH and FSH showed almost no
response. On the other hand, L-dopa ad-
ministration induced normal plasma GHRH
response in 2 cases but no response in 2
cases. Plasma GH did not increase in any













































































































































































































































































































































































































































































































































ooo rf) oo Lr)
















































































































































































































































































































































































































































































































(ltu/3d)HttЭV e uSeld(ILu/8u)¬dd (l uJ/∩luJ)HSJ eu」Seld






















































































































































































































































































































































































































































































































































































































































































































































































































































































Vol. 36, No. 5 FOUR RELEASING HORMONE TEST AND L-DOPA TEST
of the patients (Fig. 6).
The results of the 4RHs test in 7
patients with hypopituitarism due to pitui-
tary apoplexy (cases l0 and I 1) or due to
resection of a pituitary tumor (cases 12-16)
are shown in Fig. 7. Plasma GH showed
a low response or none at all. Four cases
revealed a subnormal ACTH response with
an increase in plasma cortisol (data not
shown), and in three cases there was no
ACTH or cortisol response. Plasma TSH
showed a normal or subnormal response in
6 cases, and case I 2 showed a delayed
response. Plasma PRL showed a low re-
sponse in 5 out of 7 patients. Plasma LH
showed no response in cases 12 and l3
and a subnormal response in the other 4
cases. Plasma FSH showed no response in
case I3 and other 4 cases a subnormal
response. In contrast, L-dopa test revealed
a normal response of plasma GHRH in 6
out of 7 patients, but a normal response of
plasma GH was found only in case 14 and
in the others there was almost no plasma
GH response (Fig. 8).
Patients uith ACTH deficiency syn-
drome
The results of the 4RHs test in 3
patients with ACTH deficiency syndrome
(cases 17, 18 and 19) are shown in Fig. 9.
In case 17, all anterior pituitary hormones
except ACTH showed normal responses.
Case 18 had no plasma ACTH or GH
response. The basal plasma ACTH level
is not detectable in case 19, but his plasma
ACTH and cortisol were slightly increased
after the administration of 4RHs (data
not shown). In addition, plasma TSH
showed a rather strong response in these 3
cases. On the other hand, plasma GHRH
showed a subnormal response to L-dopa in
all 3 patients (Fig. l0). Plasma GH did
not increase in case 8, and there was only
a subnormal increase in the other 2 cases.
Patients with anorexia neroosa
The results of the 4RHs test in 7
patients with anorexia nervosa (case 20-26)
are shown in Fig. I l. Basal and peak
plasma GH concentrations were 4.2 ng/ml
and 55.4 ng/ml, respectively, and significantly
higher than in normal controls (p < 0.01).
Peak plasma ACTH was lower than that
of the controls (p<0.05). Plasma TSH
showed a hyper- and delayed response.
Peak plasma PRL was similar to that of
the controls. but reached later. Plasma
LH showed a low (p(0.01) and delayed
response, and plasma FSH also showed a
delayed response.
As shown in Fig. 12, basal plasma
GHRH was slightly higher rhan that of the
controls, but the difference was not signi-
ficant. Plasma GHRH and GH did not
increase after L-dopa administration. Peak
GHRH and GH were significantly lower
than those of the controls (R(0.01, both).
Discussion
Until recently, the function of the
anterior pituitary has been evaluated by
provocative tests with various secretagogues
including hypothalamic releasing hormones.
However, this requires several loading tests
to examine a patient. Then TRH and
LHRH were combined with each other
(Saito er al., 1972) and with insulin (Lufkin
et al., 1983) as a single test of the release
of multiple anterior pituitary hormones.
After the discovery of CRH and GHRH,
Sheldon et ol. (1985), Cohen et al. (1986)
and Kogure (1987) reported that the
combined administration of 4RHs caused
no apparent inhibition or synergism with
respect to the individual hormone responses
compared to the separate administration of
TRH, LHRH, CRH and GHRH. Therefore,
they concluded that the 4RHs test is a
rapid, safe and useful test of combined
anterior pituitary function. The dose used
BANDO
in our study on the combined test was 100
pg for LHRH, CRH and GHRH and 500
pg for TRH, and proved sufficient to
stimulate the release of LH, FSH, ACTH,
GH and TSH in normal subjects.
On the other hand, we have developed
a RIA for GHRH and investigated the
correlation between plasma GHRH and
plasma GH in normal and diseased states,
including idiopathic pituitary dwarfism,
acromegaly and ectopic growth hormone-
releasing hormone (GHRH) syndrome (Saito
et al., 1984; Sano et al., 1984, 1986, 1987;
Yamasaki et al., l988a,b). It was reported
that clonidine, insulin and ornithine in-
creased plasma GH, but not plasma GHRH
(Donnadieu et al., 1985; Tapanainen et al.,
1988). However, we found that L-dopa
stimulates the release of GHRH resulting
in an increase in plasma GH (Saito et al.,
1984), and this was confirmed by Donnadieu
et al. (1985), Chihara et al. (1986) and
Tapanainen et al. (1988). Plasma GHRH
reached a peak 30 to 90 min after L-dopa
administration. This is at least in part due
to the difference in the time taken to
absorb L-dopa from the intestine in each
subject. The increase in plasma GHRH is
synchronized with or followed by that of
plasma GH in normal subjects, suggesting
that GH response to L-dopa is mediated
by the release of GHRH from the hypo-
thalamus. Therefore, the L-dopa test is
thought to be useful in evaluating hypo-
thalamic-pituitary function on the basis of
the response of plasma GHRH and GH.
Thus, we applied the combination of the
4RHs test and L-dopa test to evaltrate
hypothalamic-pituitary function in the
patients with hypothalamic and/or pituitary
disorders.
In the patients with hypothalamic dis-
orders, plasma GH response to the 4RHs
test was normal or low. This suggests that
these patients have normal or impaired GH
secretion secondary to a hypothalamic dis-
order. However, the L-dopa load failed to
Endocrinol. Japon.
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increase plasma GHRH and GH in these
patients. This finding suggests that hypo-
thalamic GHRH was not released in re-
sponse to L-dopa because of a hypothalamic
disorder, resulting in failure to release GH
from the pituitary. Three cases examined
by insulin hypoglycemia and arginine load
showed no GH response, confirming the
existence of a hypothalamic disorder also.
Consequently, the patients with hypothalamic
?isorders seem to have a normal or sub-
normal response of plasma GH to the
4RHs test and no response to the L-dopa
test. Therefore, the combination of both
tests is useful and feasible in examining
the hypothalamic-pituitary function of the
patients with hypothalamic disorders.
Plasma ACTH and cortisol showed
almost normal responses in our patients,
suggesting that the function of the ACTH-
cortisol axis may be preserved for a rather
long time, even if the secretions of other
anterior pituitary hormones are secondarily
impaired by hypothalamic disorders. The
increase in basal plasma PRL and the
strong response of plasma PRL to 4RHs
were observed in cases l, 2 and 4, probably
due to impaired secretion of prolactin in-
hibiting factor (eIf) from the hypothalamus
because of hypothalamic lesions. On the
other hand, case 3 had a weak response of
plasma PRL to the 4RHs test, suggesting
a complication of hypopituitarism caused
by invasion of the pituitary by a cranio-
pharyngioma. In a patient with Hand-
Schliller-Christian disease, her plasma LH
and FSH firstly showed a weak response
to the 4RHs test, but responded gradually
to normal after repeated pulsatile injections(l0pg every 2h) of LHRH. This indicates
that her hypogonadism is induced by a
hypothalamic lesion due to Hand-Schi.iller-
Christian disease contracted at the age of
3. The patient with Prader-Willi syndrome
(case 5) had typical clinical signs, and
seemed to have mainly hypothalamic dys-
function, because of similar responses of
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anterior pituitary hormones to those in the
patients with hypothalamic disorders.
As for hypopituitarism, the patients
were divided into two groups : one is idio-
pathic and postpartum hypopituitarism, and
the other is hypopituitarism due to pituitary
apoplexy and resection of a pituitary tumor.
In the 4RHs test, the former showed no
response of plasma gonadotropin. In con-
trast, plasma GHRH was increased in
response to L-dopa in 2 of 4 cases, although
plasma GH did not increase in all patients.
These data indicate that in some cases with
the Sheehan's syndrome, secretion of GHRH
was impaired, followed by a decrease in
GH release and that the release of GH and
gonadotropin was more easily blunted than
that of ACTH and TSH. Two cases had
a normal basal ACTH level, but little re-
sponse to CRH. This also suggests a re-
duction in pituitary ACTH reserve in these
patients as well as the 2 patients in Fig.
7. In the latter group, the response of
plasma anterior pituitary hormones to the
4RHs test was mostly below the normal
range. However, plasma GHRH was in-
creased in 6 of 7 cases, although plasma
GH was increased in only one case (case
14) in the L-dopa test. These data suggest
that the patients with hypopituitarism due
to pituitary adenoma have GHRH-secreting
capacity unless the tumor invades the hypo-
thalamus.
Stacpoole et al. (1982) reported that
ACTH deficiency syndrome can be classified
into three groups : I ) Isolated ACTH
deficiency due to pituitary defect or supra-
pituitary defect, 2) limited ACTH reserve,
and 3) combined pituitary insufficiency. To
diagnose this syndrome, provocative tests
for all anterior pituitary hormones are re-
quired. The combined test make it possible
at once, and the L-dopa test is also helpful
in investigating the possibility of a compli-
cation by a hypothalamic lesion. Case 17
showed no response of ACITH alone and
a normal response of other pituitary hor-
mones, indicating typical isolated ACTH
deficiency. In case 18, no responses of
ACTH or GH to the 4RHs test was
observed, and this suggested a combined
type of ACTH deficiency syndrome as-
sociated with GH deficiency. However,
plasma GH responded to GHRH after
supplementation with cortisol in this patient.
Giustina et al. (1989) reported that growth
hormone deficiency observed in the patients
with idiopathic ACTH deficiency was re-
covered during glucocorticoid replacement,
and suggested that a physiological level of
serum cortisol is necessary for GH release
in response to secretagogues in man.
Furthermore, Hochberg et al. (1985) re-
ported patients with both isolated ACTH
deficiency and transitory GH deficiency.
The pituitary reserve of ACTH and GH in
case 18 is similar to the results reported
by these authors. Case l9 had clinical
manifestations of adrenal insufficiency, de-
creased urinary excretion of l7-OHCS
and an undetectable basal level of plasma
ACTH. However, the plasma concentrations
of ACTH and cortisol were slightly in-
creased during the combined test, suggesting
the condition of limited ACTH reserve
described by Stacpoole et al. (1982).
These 3 cases had normal thyroid
function but showed a strong response ol
plasma TSH to the 4RHs test. A strong
response of both TRH and PRL to TRH
was previously reported by Mashito er a/.(1981) and Gonzalez and Werk (1985) in
untreated isolated ACTH deficiency. This
may be related to the absence of glucocor-
ticoid because of the normalized response
of plasma TSH and PRL after glucocorticoid
replacement, but the mechanism is still not
known. On the other hand, L-dopa evoked a
normal response of plasma GHRH in these
three cases, suggesting no apparent lesion in
the region of the arcuate nucleus where the
GHRH neurons are located. Therefore, the
patients seemed to have a pituitary defect.




case l8 (ACTH deficiency with GH de-
ficiency) revealed no response. This finding
is compatible with the hypothesis of Giustina
et al. (1989) and indicates that glucocorticoid
replacement is necessary before examining
GH-secreting activity in the patients with
ACTH deficiency syndrome. This also offers
a key to the mechanism ol interaction be-
tween the GHRH-GH axis and the ACTH-
cortisol axis.
In the patients with anorexia nervosa,
the 4RHs test revealed a significant change
in anterior pituitary function. The in-
creased basal GH concentration and strong
response of plasma GH to the 4RHs test
are compatible with previous reports (Taka-
no, 1986; Masuda et al., 1988). Plasma
ACTH showed a low response, and plasma
cortisol did not increase significantly (data
not shown). These findings suggest that
hypersecretion of CRH may occur in
patients with anorexia nervosa (Hotta et
al., 1986). Plasma TSH showed a delayed
response, that may be related not only to
an eating disorder but also to weight loss
(Kiyohara et al., 1987). Plasma PRL re-
sponse was within the normal range as
previously reported (Karibe et al., 1988),
although Waldhauser et al. (1984) described
a weak response of PRL to TRH. De-
creased response of plasma LH is consistent
with previous reports and plasma FSH
showed a delayed response similar to plasma
LH (Sherman et al., 1975). No responses
of plasma GHRH or GH to L-dopa indicate
the impairment of hypothalamic function
in patients with anorexia nervosa.
In conclusion, we were the first to report
the clinical significance of the combination
of the combined 4RHs test and L-dopa test,
especially by measuring the responses of
plasma GHRH and six anterior pituitary
hormones. The combination of both tests
is a simple and useful means to use in
evaluating hypothalamic-pituitary function
in normal subjects and in the patients with
hypothalamic andTor pituitary disorders.
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